NCT05186922

The Study of CM326 in Patients With Moderate-to-severe Atopic Dermatitis

A Randomized, Double Blind, Placebo-Controlled, Multiple Dose Escalation, Phase 2 Study to Evaluate the Safety, Tolerance, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Preliminary Efficacy of CM326 in Patients With Moderate-severe Atopic Dermatitis Subjects

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 54 (estimated)
• Sponsor: Keymed Biosciences Co.Ltd · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a multi-center, randomized, double blind, placebo-controlled multiple dose escalation study to evaluate the safety, tolerance, PK, PD, immunogenicity and preliminary efficacy of CM326 in moderate-severe AD subjects.

Detailed description

The study consists of 3 periods, a up-to-4-week Screening Period, a 12-week randomized Treatment Period and a 12-week Safety Follow-up Period.

Conditions

• Moderate-to-severe Atopic Dermatitis

Interventions

Type	Name	Description
BIOLOGICAL	CM326	CM326 injection
OTHER	Placebo	Placebo

Timeline

• Start date: 2022-02-17
• Primary completion: 2023-01-01
• Completion: 2023-01-01
• First posted: 2022-01-11
• Last updated: 2022-03-09

Locations

1 site across 1 country: China